a pioneer in metagenomic next-generation sequencing (mNGS) for infectious diseases, today announced data presented at IDWeek 2025™ in Atlanta, Ga., by researchers from Columbia University Irving Medical Center show metagenomic sequencing that detects both RNA and DNA pathogens, available through Delve…
Iambic Therapeutics, a clinical-stage life science and technology company developing novel medicines using its AI-driven discovery and development platform, today announced clinical data for IAM1363, a brain-penetrant HER2 small-molecule tyrosine kinase inhibitor (TKI), which showed anti-tumor activity in heavily pretreated…
Mosaic Therapeutics, Ltd, (‘Mosaic’, or ‘the Company’) an oncology therapeutics company building the category leader in Synergistic Precision Oncology, today announced the appointment of Thomas Fuchs as CEO. Thomas will lead the Company to advance its pipeline of proprietary drug…
announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma…
For decades, traditional adrenaline auto-injectors (AAIs) have been the only available treatment for anaphylaxis—a life-threatening allergic reaction.1,2 Yet from today, the UK’s first needle-free emergency anaphylaxis treatment, the EURneffy® nasal adrenaline spray, is available on prescription.3 EURneffy® 2 mg nasal spray offers a…
(Nasdaq: EXEL) today announced detailed results from STELLAR-303, a global phase 3 pivotal trial evaluating zanzalintinib in combination with atezolizumab (Tecentriq®) versus regorafenib in patients with previously treated non-microsatellite instability (MSI)-high metastatic colorectal cancer (CRC). As previously announced, the study met…
DATROWAY® Demonstrates Significant Survival Benefit Over Chemotherapy in First-Line Metastatic Triple-Negative Breast Cancer in TROPION-Breast02 Trial Positive results from the pivotal TROPION-Breast02 phase 3 trial have shown that DATROWAY® (datopotamab deruxtecan) delivers a statistically significant and clinically meaningful improvement in…
DESTINY-Breast05 Phase III Trial Demonstrates ENHERTU® Significantly Reduces Recurrence Risk in High-Risk HER2-Positive Early Breast Cancer Positive results from the DESTINY-Breast05 Phase III trial have demonstrated that ENHERTU® (fam-trastuzumab deruxtecan-nxki) provides a highly statistically significant and clinically meaningful improvement in…
Genmab Reports Promising New Data Showing Rina-S® Demonstrates Strong Anti-Tumor Activity in Advanced Endometrial Cancer Genmab A/S (Nasdaq: GMAB) announced new and encouraging results from its Phase 1/2 RAINFOL™-01 clinical trial evaluating rinatabart sesutecan (Rina-S®), an investigational folate receptor alpha…
Eikon Therapeutics, Inc., a late-stage clinical biopharmaceutical company focused on integrating advanced engineering with cutting-edge laboratory and in silico research to accelerate drug discovery, today announced that new data from its ongoing Phase 2 study of EIK1001 (TeLuRide-005) will be…